Prosecution Insights
Last updated: November 04, 2026
Application No. 18/235,036

Method and System for Treating Depression and Other Mental Disorders

Non-Final OA §103
Filed
Aug 17, 2023
Examiner
SPAINE, ROBERT FRANKLIN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Snowfall Psychedelics LLC
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
8 granted / 10 resolved
+20.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
56 currently pending
Career history
59
Total Applications
across all art units

Statute-Specific Performance

§101
14.4%
-25.6% vs TC avg
§103
36.6%
-3.4% vs TC avg
§102
8.3%
-31.7% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 10 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group II, claims 13-18, drawn to a pharmaceutical composition and a kit in the reply filed on July 1st, 2026 is acknowledged. Claims 1-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. The requirement is deemed proper and therefore made FINAL. Claims 13-18 are pending and were examined on the merits. Information Disclosure Statement The information disclosure statement (IDS) filed July 10th, 2025 fails to comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609 because there are no provided legible copies of the non-patent literature documents cited on the IDS. The illegibility of the provided copies of these documents may be caused by text that is too small relative to the soft scanning resolution of the document. The IDS has been placed in the application file, but the information referred to therein has not been considered as to the merits for the lined-through citations. Applicant is advised that the date of any re-submission of any item of information contained in this information disclosure statement or the submission of any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the statement, including all certification requirements for statements under 37 CFR 1.97(e). See MPEP § 609.05(a). Drawings The drawings were received on August 17th, 2023. These drawings are acceptable. Specification The disclosure is objected to because of the following informalities: the specification does not recite the full names of the. Appropriate correction is required. Claim Objections Claims 13 and 16 are objected to because of the following informalities: these claims are independent claims and they do not recite the full name of the abbreviated term "MDMA" at first mention. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 13-18 are rejected under 35 U.S.C. 103 as being unpatentable over Emanuel (KR 20230006554 A). Claim 13 recites “A pharmaceutical composition for treating depression, comprising a therapeutically effective amount of psilocybin and MDMA, wherein the composition is formulated for oral administration”. Claim 14 recites “The pharmaceutical composition of claim 13, wherein the composition is in the form of a tablet”. Claim 15 recites “The pharmaceutical composition of claim 14, wherein the composition is in the form of a liquid solution”. Claim 16 recites “A kit for treating depression, comprising: a first component including psilocybin; a second component including MDMA; and instructions for administering the psilocybin and MDMA to a subject”. Claim 17 recites “The kit of claim 16, wherein the instructions direct that the MDMA is to be administered prior to the administration of psilocybin”. Claim 18 recites “The kit of claim 16, wherein the instructions direct that the psilocybin and the MDMA are to be administered concurrently”. The applicant is notified that when reading the preamble in the context of the entire claim, the recitation "for treating depression" (claims 13 and 16) is not limiting because the body of the claim describes a complete invention and the language recited solely in the preamble does not provide any distinct definition of any of the claimed invention’s limitations. Thus, the preamble of the claims is not considered a limitation and is of no significance to claim construction. See Pitney Bowes, Inc. v. Hewlett-Packard Co., 182 F.3d 1298, 1305, 51 USPQ2d 1161, 1165 (Fed. Cir. 1999). See MPEP § 2111.02. Emanuel recites the technical field of their invention “The present invention relates to compositions and methods for enhancing the affective and therapeutic effects of psychedelics” (machine translation, page 2 of 17, lines 9 and 10 from the top; claim 13). Emanuel recites “MDMA is preferably administered at a dose of 20 mg to 200 mg” (machine translation, page 4 of 17, lines 6-7 from the top; instant claim 13). Emanuel recites hallucinogens in their invention, including psilocybin: “The hallucinogens used in the method of the present invention are psilocybin, psilocin, lysergic acid diethylamide (LSD), mescaline, dimethyltryptamine (DMT), 2,5-dimethoxy-4 -iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamine (DOB), other phenethylamine or tryptamine hallucinogens, salts thereof, analogues thereof or prodrugs thereof or analogues thereof; Not limited. Any suitable dose may be used, several examples are provided below. The mechanism of action of hallucinogens is described below” (machine translation, page 4 of 17, lines 9-13 from the top; instant claim 13). Although Emanuel does not recite a specific dosage of psilocybin, it is implied from the technical field of the invention of Emanuel, that the dose is therapeutically effective (instant claim 13). Emanuel provides some guidance for manipulating the dose of hallucinogens: “One solution to deal with adverse drug effects is to reduce the dose of hallucinogens, but this can also at least partially reduce the good drug effects” (machine translation, page 2 of 17, lines 2 and 3 from the bottom; instant claim 13). Emanuel recites administering MDMA before, simultaneously with, or after administration of the hallucinogen: “In the present invention, MDMA can be administered prior to, simultaneously with, or typically after administration of the hallucinogen, or even before or after depending on the pharmacokinetics of the formulation to be used” (machine translation, page 4 of 17, lines 17-19 from the bottom; claims 13 and 16-18). Emanuel recites combining psilocybin with MDMA, and administering MDMA before, concurrently with, or after psilocybin: “When combined with psilocybin, MDMA may also be administered before, concurrently with, or after psilocybin, but for purposes of this invention it will best occur before or with psilocybin” (machine translation, page 5 of 17, lines 7-9 from the top; claims 13 and 16-18). Emanuel recites routes of administration “In the method of the present invention, the compound of the present invention can be administered in a variety of ways. It should be noted that it can be administered as a compound, administered alone or as an active ingredient in combination with pharmaceutically acceptable carriers, diluents, adjuvants and vehicles. The compounds may be administered orally, subcutaneously or parenterally, including intrathecal and infusion techniques as well as intravenous and intranasal administration. Implants of the compound are also useful. The patient under treatment is a warm-blooded animal, particularly a mammal, including humans. Pharmaceutically acceptable carriers, diluents, adjuvants and vehicles, as well as implant carriers, generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating materials that do not react with the active ingredients of the present invention” (machine translation, page 6 of 17 lines 1-5 from the bottom, and page 7 of 17 lines 1-4 from the top; claims 13-15). Although Emanuel does not explicitly recite the physical form of a tablet, the recitation of oral administration and non-toxic solid fillers in the above quote implies that administration of a composition in tablet form is within the purview of the skilled artisan, and a tablet is at least obvious to try as one of a finite number of potential physical forms to solve the problem of oral administration of a therapeutic composition (instant claim 14). Emanuel does not explicitly recite the physical form of a liquid solution but does recite oral administration and non-toxic liquid fillers in the cited quote above. Furthermore, considering the mixed polar/non-polar molecular structures of MDMA and psilocybin, a person of skill in the art could reasonably dissolve these compounds using a polar amphiphilic solvent such as ethanol or glycerol. Therefore, formulating a composition comprising MDMA and psilocybin into a liquid solution is within the purview of the skilled artisan. A liquid solution is at least obvious to try as one of a finite number of potential physical forms to solve the problem of oral administration of a therapeutic composition (instant claim 15). Emanuel is relied upon for the reasons discussed above. If not expressly taught thereby, based upon the overall beneficial teachings provided by the reference with respect to providing the combination of psilocybin and MDMA, the adjustments of particular conventional working conditions (e.g., the selection from among known components and determining one or more suitable ranges (amounts, proportions, ratios thereof) in which to provide the pharmaceutical composition), is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. From the teachings of Emanuel, the invention as a whole, drawn to a pharmaceutical composition as described in Claims 13-18, would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, and one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention, as evidenced by the reference, especially in the absence of evidence to the contrary. Please note, since the Office does not have the facilities for examining and comparing Applicants’ composition with the composition of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and the product of the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald, 619 F.2d 67, 205 USPQ 594 (CCPA 1980), and “as a practical matter, the Patent Office is not equipped to manufacture products by the myriad of processes put before it and then obtain prior art products and make physical comparisons therewith.” In re Brown, 459 F.2d 531, 535, 173 USPQ 685, 688 (CCPA 1972). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert F Spaine whose telephone number is (571)272-9099. The examiner can normally be reached 8:00 AM - 4:00 PM United States Eastern Time, Monday-Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571) 272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /R.F.S./Examiner, Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Aug 17, 2023
Application Filed
Oct 16, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773438
METHOD OF EXTRACTION OF PROANTHOCYANIDINS COMPOUND FROM PINE BARK OF PINUS ROXBURGHII
2y 11m to grant Granted Oct 27, 2026
Patent 12751986
COMPOSITION FOR INHIBITING PROLIFERATION OF TUMOR COMPRISING RUBUS COREANUS EXTRACT AS EFFECTIVE COMPONENT
2y 10m to grant Granted Oct 06, 2026
Patent 12728144
Composition Based on Natural Ingredients and Use of the Composition for Improving Mental Health
4y 2m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 3 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
80%
With Interview (+0.0%)
2y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 10 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month